Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the
过去5年,Mauna Kea Technologies SAS的标准化净利润在dezembro 2023达到了 -6.356百万的峰值。 Mauna Kea Technologies SAS的标准化净利润于dezembro 2019触及5年低点,是-9.541百万。 Mauna Kea Technologies SAS的标准化净利润于2019 (-9.541百万, +19.4%)减少和于2020 (-8.14百万, -14.7%)、2021 (-7.846百万,...
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the
Paris and Boston, July 25, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces its unaudited sales and achievement...
Mauna Kea Technologies的汇兑收益(损失)于dezembro 2022触及5年低点,是-494.7千。 Mauna Kea Technologies的汇兑收益(损失)于2020 (-87.955千, +50.8%)、2021 (-283.405千, +222.2%)和2022 (-494.7千, +74.6%)减少和于2019 (-58.329千, -69.9%)和2023 (-18.768千, -96.2%)增加。
LocationMauna Kea Technologies SA9, rue d'EnghienPARIS 75010FranceFRA Phone+33 148240345 Fax+33 148241218 Websitehttps://www.maunakeatech.com/ Peer analysis Key Information CompanyRevenue (TTM)Net income (TTM)Market capEmployees Aton SA 1.56k -563.57k 8.24m 17.00 Spineguard SA 4.52m -3.78m 10...
www.maunakeatech.com MKEAF Revenue Period: RevenueRevenue Estimate MKEAF Revenue and Revenue Estimate Bar chart with 2 data series. Chart represents MKEAF Revenue and Revenue Estimate over Annual period The chart has 1 X axis displaying time periods. ...
法国Mauna Kea Technologies (MKT) 公司研发製造的小动物活体共軛焦系统(Cellvizio),可用於小动物全身组织实现细胞等级成像,让实验者不需大量牺牲动物进行切片染色。此套系统已被广泛应用在神经科学、肿瘤研究、干细胞研究、心血管研究、萤光奈米粒子研究、药物研究、动物行為科学等领域。另外MKT也有应用於临床上的光纤探头...
Mauna Kea Technologies宣布,作为其与强生公司肺癌计划("LCI")合作的一部分,在由LCI赞助的前瞻性,多中心,开放标签,单臂临床可行性研究中,已开始对患者进行初始招募。该研究将结合nCLE和机器人辅助支气管镜检查,使用Cellvizio和Auris Health,Inc.的Monarch®平台,以评估nCLE准确确认针头位置以诊断外周肺结节的能力(http...
最近访问:MAUNA KEA TECHNOLOGIES ORD SHS --- - -- 今开: - 最高价: - 成交量: - 外盘: - 昨收: - 最低价: - 成交额: - 内盘: - 总股本: - 振幅: - 换手率: - 每股收益TTM: - 总市值: - 市净率MRQ: - 市盈率TTM: - 每股净资产: - ...